Compare AstraZeneca plc (AZN) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Salesforce Inc — how do they compare? AstraZeneca plc trades at $158.23 (market cap $248.14B), while Salesforce Inc trades at $192.42 (market cap $161.73B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | CRM | |
|---|---|---|
Market Cap | $248.14B | $161.73B |
Sector | Health | Technology |
52-Week High | $209.48 | $266.23 |
52-Week Low | $147.06 | $150.12 |
Enterprise Value | $275.41B | $191.77B |
Dividend Yield | 2.01% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Salesforce (CRM) trades at $192.28, down 2.65% today amid a broader tech sell-off, but maintains strong fundamentals with consistent earnings beats, robust profitability margins, and solid cash flow growth. The stock exhibits a bullish technical trend with key support at $193, while analyst consensus remains overwhelmingly positive with a $230.83 price target. Recent news highlights AI-driven growth potential but also sector-wide volatility concerns.
Outlook is favorable given CRM's rule of 44 performance, AI monetization momentum, and discounted valuation, though risks include competitive pressures, macroeconomic headwinds, and elevated RSI levels suggesting near-term overbought conditions. The company's double-digit revenue growth and expanding margins support long-term upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
